1. Leligdowicz A, Fischer WA 2nd, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care. 2016; 20(1): 217. doi: 10.1186/s13054-016-1325-2
2. Wambani RJ, Ogola PE, Arika WM, Rachuonyo HO, Burugu MW. Ebola virus disease: A biological and epidemiological perspective of a virulent virus. J Infect Dis Diagn. 2016; 1: 103. Website. http://ir-library.ku.ac.ke/handle/123456789/14250. Accessed May 24, 2017.
3. Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol. 2013; 4: 267. doi: 10.3389/fmicb.2013.00267
4. Laupland KB, Valiquette L. Ebola virus disease. Can J Infect Dis Med Microbiol. 2014; 25(3): 128-129. doi: 10.1155/2014/527378
5. Chan M. Ebola virus disease in West Africa — No early end to the outbreak. N Engl J Med. 2014; 371(13): 1183-1185. Website. http://www.nejm.org/doi/pdf/10.1056/nejmp1409859. Accessed May 24, 2017.
6. Urbanowicz RA, McClure CP, Sakuntabhai A, et al. Human adaptation of Ebola virus during the West African outbreak. Cell. 2016; 167(4): 1079-1087e5. doi: 10.1016/j.cell.2016.10.013
7. Uyeki TM, Mehta AK, Davey RT, Jr., et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016; 374(7): 636-646. doi: 10.1016/j. cell.2016.10.013
8. Team WER. After Ebola in West Africa — Unpredictable risks, preventable epidemics. N Engl J Med. 2016; 375(6): 587- 596. doi: 10.1056/NEJMsr1513109
9. Burghardt K, Verzijl C, Huang J, Ingram M, Song B, Hasne M-P. Testing modeling assumptions in the West Africa Ebola outbreak. Sci Rep. 2016; 6: 34598. doi: 10.1038/srep34598
10. Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: Implications for vaccines and therapies. J Virol. 2003; 77(18): 9733-9737. doi: 10.1128/JVI.77.18.9733-9737.2003
11. Lai KY, Ng WYG, Cheng FF. Human Ebola virus infection in West Africa: A review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty. 2014; 3 3(1): 43. doi: 10.1186/2049-9957-3-43
12. Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, Muhlberger E. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology. 2013; 441(2): 135-145. doi: 10.1016/j.virol.2013.03.013
13. Diehl WE, Lin AE, Grubaugh ND, et al. Ebola virus glycoprotein with increased infectivity dominated the 2013-2016 Epidemic. Cell. 2016; 167(4): 1088-1098.e6. doi: 10.1016/j. cell.2016.10.014
14. Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 2001; 286(2): 384-390. doi: 10.1006/viro.2001.1012
15. Kondratowicz AS, Maury WJ. Ebola virus: A brief review of novel therapeutic targets. Future Microbiol. 2012; 7(1): 1-4. doi: 10.2217/fmb.11.110
16. Mehedi M, Falzarano D, Seebach J, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011; 85(11): 5406-5414. doi: 10.1128/JVI.02190-10
17. Blaney JE, Wirblich C, Papaneri AB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011; 85(20): 10605-10616. doi: 10.1128/JVI.00558-11
18. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002; 8(5): 503-507. doi: 10.3201/eid0805.010284
19. Halfmann P, Ebihara H, Marzi A, et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol. 2009; 83(8): 3810- 3815. doi: 10.1128/JVI.00074-09
20. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol. 2007; 18(6): 546-556. doi: 10.1016/j.copbio.2007.10.010
21. Ura T, Okuda K, Shimada M. Developments in viral vectorbased vaccines. Vaccines. 2014; 2(3): 624-641. doi: 10.3390/vaccines2030624
22. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology. 2006; 344(1): 230-239. doi: 10.1016/j.virol.2005.09.020
23. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408(6812): 605-609. doi: 10.1038/35046108
24. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010; 28(4): 950-957. doi: 10.1016/j. vaccine.2009.10.145
25. Wu S, Kroeker A, Wong G, et al. An adenovirus vaccine expressing Ebola virus variant makona glycoprotein is efficacious in guinea pigs and nonhuman primates. J Infect Dis. 2016; 214(suppl 3): S326-S332. doi: 10.1093/infdis/jiw250
26. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014; 20(10): 1126-1129. doi: 10.1038/nm.3702
27. Quinn KM, Zak DE, Costa A, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest. 2015; 125(3): 1129-1146. doi: 10.1172/JCI78280
28. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med. 2012; 4(158): 158ra146. doi: 10.1126/scitranslmed.3004582
29. O’Brien LM, Stokes MG, Lonsdale SG, et al. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knockout mouse. Virology. 2014; 452-453: 324-333. doi: 10.1016/j. virol.2013.03.028
30. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 2010; 6(5): e1000904. doi: 10.1371/journal.ppat.1000904
31. Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines. 2015; 3(5-6): 125-138. doi: 10.1177/205101361 5611017
32. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010; 29(2): 304-313. doi: 10.1016/j.vaccine.2010.10.037
33. Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015; 385(9984): 2272-2279. doi: 10.1016/S0140- 6736(15)60553-0
34. Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011; 85(9): 4222-4233. doi: 10.1128/JVI.02407-10
35. Colloca S, Folgori A, Ammendola V, et al. Generation and screening of a large collection of novel simian Adenovirus allows the identification of vaccine vectors inducing potent cellular immunity in humans: A range of novel simian adenoviral vectors, which are capable of priming high levels of T cell responses in man, has been defined. Sci Transl Med. 2012; 4(115): 115ra2- 115ra2. doi: 10.1126/scitranslmed.3002925
36. Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine. 2016; 34(4): 413-423. doi: 10.1016/j. vaccine.2015.11.062
37. Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: A randomized clinical trial. JAMA. 2016; 315(15): 1610-1623. doi: 10.1001/ jama.2016.4218
38. Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: A phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016; 16(1): 31-42. doi: 10.1016/S1473-3099(15)00362-X
39. De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebocontrolled, dose-finding, phase 1/2a study. Lancet Infect Dis. 16(3): 311-320. doi: 10.1016/S14733099(15)00486-7
40. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine — Preliminary report. N Engl J Med. 2017; 376: 928-938. doi: 10.1056/NEJMoa1410863
41. Zhang Q, Seto D. Chimpanzee adenovirus vector ebola vaccine — Preliminary report. N Engl J Med. 2015; 373(8): 775- 776. doi: 10.1056/NEJMc1505499#SA1
42. Group TPIW. A Randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016; 375(15): 1448-1456. doi: 10.1056/NEJMoa1604330
43. Zhou Y, Sullivan NJ. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr Opin Immunol. 2015; 35: 131-136. doi: 10.1016/j.coi.2015.06.006
44. Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016; 374(17): 1635-1646. doi: 10.1056/ NEJMoa1411627
45. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J Virol. 2009; 83(14): 7296-7304. doi: 10.1128/JVI.00561-09
46. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus–based vaccines against Ebola and marburg virus infections. J Infect Dis. 2011; 204(Suppl 3): S1075-S1081. doi: 10.1093/ infdis/jir349
47. Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012; 6(3): e1567. doi: 10.1371/journal. pntd.0001567
48. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005; 11(7): 786-790. doi: 10.1038/nm1258
49. Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014; 32(43): 5722-5729. doi: 10.1016/j. vaccine.2014.08.028
50. Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus–vectored Ebola vaccine after needlestick. JAMA. 2015; 313(12): 1249-1255. doi: 10.1001/jama.2015.1995
51. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016; 374(17): 1647-1660. doi: 10.1056/NEJMoa1502924
52. Skrip LA, Galvani AP. Next steps for Ebola vaccination: Deployment in non-epidemic, high-risk settings. PLoS Negl Trop Dis. 2016; 10(8): e0004802. doi: 10.1371/journal.pntd.0004802
53. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine – Preliminary report. N Engl J Med. 2015; 376: 330-341. doi: 10.1056/NEJMoa1414216
54. Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015; 15(10): 1156-1166. doi: 10.1016/ S1473-3099(15)00154-1
55. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015; 386(9996): 857-866. doi: 10.1016/S0140-6736(15)61117-5
56. Li H, Ying T, Yu F, Lu L, Jiang S. Development of therapeutics for treatment of Ebola virus infection. Microbes Infect. 2015; 17(2): 109-117. doi: 10.1016/j.micinf.2014.11.012